TNDM Form 4: John F. Sheridan Acquires 10K Shares on 08/11/2025

Rhea-AI Filing Summary

John F. Sheridan, President & CEO and director of Tandem Diabetes Care, Inc. (TNDM), reported a non-derivative purchase of 10,000 shares on 08/11/2025. The filing states the trades executed at prices ranging from $10.19 to $10.33, with a weighted average purchase price of $10.2318. Following the reported transaction, the reporting person beneficially owned 106,327 shares.

The Form 4 identifies the filing as by one reporting person and includes an explanatory note that full details of the multiple trades (number of shares per trade and individual prices) will be provided upon request. The form is signed by Rachel Malina as attorney-in-fact for John F. Sheridan.

Positive

• Insider purchase recorded: CEO/Director John F. Sheridan acquired 10,000 shares on 08/11/2025 at a weighted average price of $10.2318.
• Post-transaction ownership disclosed: Beneficial ownership increased to 106,327 shares following the reported purchase.

Negative

• None.

Insights

Securities Analyst

TL;DR: The CEO purchased 10,000 shares at a $10.2318 weighted average, raising direct beneficial ownership to 106,327 shares.

The Form 4 documents a straightforward non-derivative purchase executed on 08/11/2025 in multiple trades with prices between $10.19 and $10.33, producing a weighted average price of $10.2318. The filing shows this was reported by one person and provides a precise post-transaction ownership figure of 106,327 shares. All figures are stated explicitly in the filing; no derivative instruments or dispositions are reported. The reporting and signature details are provided in the document.

Corporate Governance Expert

TL;DR: Routine Section 16 filing: CEO/director purchase reported by attorney-in-fact, with an explanatory disclosure about multiple trades.

The submission is a standard Form 4 reporting a non-derivative acquisition by John F. Sheridan, identified as President & CEO and director. The form notes the transaction executed in multiple trades and offers to provide full trade breakdowns upon request. It is filed as a single reporting person and bears an attorney-in-fact signature, indicating compliance with filing procedures rather than unusual governance action.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sheridan John F

(Last) (First) (Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		P		10,000	A	$10.2318(1)	106,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $10.19 to $10.33 per share. The reported price reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Rachel Malina, Attorney-in-Fact for John F. Sheridan	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tandem Diabetes (TNDM) CEO John F. Sheridan report on Form 4?

The Form 4 reports a non-derivative purchase of 10,000 common shares on 08/11/2025, executed in multiple trades.

At what price did the insider purchase Tandem Diabetes (TNDM) shares?

Trades occurred between $10.19 and $10.33, with a weighted average purchase price of $10.2318.

How many Tandem Diabetes (TNDM) shares does the reporting person beneficially own after the transaction?

The filing shows 106,327 shares beneficially owned following the reported transaction.

Who filed and signed the Form 4 for John F. Sheridan?

The form is filed for one reporting person and is signed by Rachel Malina, Attorney-in-Fact for John F. Sheridan, dated 08/11/2025.

Does the Form 4 disclose detailed per-trade quantities and prices?

The form states trades were executed in multiple transactions and offers to provide full trade details upon request; individual trade breakdowns are not listed in the filing.